HEALTH
Glaxo Moves to Block Generic Zantac: The British pharmaceuticals company said it has taken legal action to block a Ciba-Geigy unit from marketing a cheap generic copy of its Zantac ulcer drug in the United States. The patent-infringement suit was filed in a New Jersey court against Geneva Pharmaceuticals Inc. Glaxo said Geneva’s plan to sell a generic Form 1 version of Zantac, beginning in 1996, would violate its patents on the newer Form 2, which has patent protection until 2002. Zantac is the world’s largest-selling prescription drug.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
